Mirvetuximab in Ovarian Cancer with Giorgio Bogani

IJGC Podcast

Inhalt bereitgestellt von BMJ Group. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von BMJ Group oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.

3M ago 26:53

MP3•Episode-Home

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Professor Giorgio Bogani to discuss Mirvetuximab in Ovarian Cancer. Prof. Bogani serves as a consultant in gynecologic oncology at the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano in Milan, Italy. He completed a research fellowship at the Mayo Clinic in Rochester, MN, USA, with a focus on endometrial cancer and gynecologic oncology. Currently, his expertise is centered on gynecological surgery and experimental medicine.

Highlights:

Mirvetuximab soravtansine-gynx is a ADC comprising a FRα-directed antibody and DM4 as payload.
High FRα expression is noted in ~35-40% of platinum-resistant high-grade serous ovarian cancer.
Mirvetuximab showed an objective response rate of about 30-35% in platinum-resistant high-grade serous ovarian cancer with high FRα tumor expression.
A promising activity mirvetuximab splus bevacizumab was observed in platinum-resistant ovarian cancer, regardless of level of FRα expression or prior bevacizumab exposure.
Emerging data highlighted the promising role of mirvetuximab in combination with carboplatin and bevacizumab in platinum-sensitive ovarian cancer patients.

360 Episoden

#Medicine #BMJ Group #Fitness #Pedro Ramirez